c-Fms激酶及其小分子抑制剂研究进展  

c-Fms kinase and its small molecule inhibitors:research advances

作　　者：赵源[1,2] 肖军海[2] 

机构地区：[1]烟台大学药学院,烟台264006 [2]军事医学科学院毒物药物研究所,北京100850

出　　处：《国际药学研究杂志》2012年第5期373-378,共6页Journal of International Pharmaceutical Research

摘　　要：c-Fms激酶是由c-fms原癌基因编码的产物,属于受体型酪氨酸激酶血小板衍生生长因子(PDGFR)家族,是巨噬细胞集落刺激因子(M-CSF)的受体。c-Fms与其配体M-CSF相互作用,对单核巨噬细胞的增殖、分化及存活起关键作用。c-Fms激酶的异常激活与多种疾病有关,特别是与恶性肿瘤和类风湿性关节炎的发生发展密切相关。因此以c-Fms激酶为靶标的小分子抑制剂为肿瘤等疾病的治疗开辟了新的途径。本文对近年来c-Fms激酶及其小分子抑制剂的研究进展进行综述。c-Fms, encoded by the c-fms proto-oncogene, is a member of the platelet derived growth factor receptor （PDGFR） family of receptor tyrosine kinases （RTK）. The interaction of c-Fms and the receptor, macrophage colony stimulating factor （M-CSF） can regulate proliferation, differentiation and survival of the mononuclear phagocyte cells. Abnormal expression of c-Fms is associated with a significant number of human pathologies, especially a variety of cancers and rheumatoid arthritis. Accordingly, c-Fms kinase can be considered as a novel choice for treating cancers and other diseases. This review describes the recent progress of c-Fms kinase and its small molecule inhibitors.

关 键 词：c-Fms激酶 抑制剂 肿瘤 小分子 抗肿瘤药 

分 类 号：R914[医药卫生—药物化学]